Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
BACKGROUND
SCOPE AND METHODOLOGY
SIZE AND GROWTH OF THE GLOBAL OTC MARKET
Figure 1-1: Global Over-the-Counter Drug Market Analysis: 2017 to 2023 (millions USD)
Global Markets
Figure 1-2: Top Twenty OTC Drug Markets, Country Market Share (%), 2017 (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia, Rest of World)
Leading Competitors
CHAPTER TWO: INTRODUCTION
BACKGROUND
DISTRIBUTION AND SAFETY ISSUES IN THE UNITED STATES
CONSUMER ADVERTISING AND PROMOTION
GLOBAL HEALTH
Global Life Expectancy
Table 2-1: Average Life Expectancy in Years by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela, Global Average)
Figure 2-1: Average Life Expectancy in Years by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
Global Trends in Birth Rates
Table 2-2: Crude Birth Rate per 1,000 Persons by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela, Global Average)
Figure 2-2: Crude Birth Rate per 1,000 Persons by Country, 2017 and Projected 2025 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
Tobacco Use
Figure 2-3: Percent of Tobacco Users as a Percentage of Population by Country, 1990 vs. 2010 (%) (Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, South Africa, Spain, Turkey, United Kingdom, United States)
Obesity
Figure 2-4: Obesity Prevalence as a Percentage of Population by Country, 2006 vs. 2016 (%) (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
Declining Growth of the Global Population
Table 2-3: Global Population 1980 to 2050 (millions)
Figure 2-5: The Global Population, 1980-2050
Figure 2-6: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
PRESCRIPTION VS. OVER-THE-COUNTER INDUSTRY
Figure 2-7: Total Pharmaceutical Markets: Prescription vs. Non-Prescription by Country, 2017 (% of total pharmaceutical market) (United States, Japan, China, Germany, France, India, Brazil, Russia, United Kingdom, Australia, Mexico, Canada, Italy, Spain, Poland, Turkey, Argentina, Venezuela, South Africa, Saudi Arabia)
OVER-THE-COUNTER DRUG PRODUCT SEGMENTS
Table 2-4: Global OTC Drug Market Analysis, Markets by Product Segment, 2017 to 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
Figure 2-8: Global OTC Drug Market Analysis, Markets by Product Segment, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
RX-TO-OTC SWITCH INDUSTRY
Table 2-5: Leading FDA approved Rx-to-OTC switches, 1994-2017
Figure 2-9: Number of New Rx-to-OTC Switches in the United States, per year 1976-2017
ECONOMIC TRENDS
Figure 2-10: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, 2010 and 2020 Estimated (%) (United States, France, Germany, Canada, Japan, United Kingdom, Australia, Italy, Spain, South Africa, Brazil, Russia, Mexico, Poland, China, Venezuela, Turkey, India, Argentina, Saudi Arabia)
Purchasing Power Trends
Figure 2-11: Gross National Income by Country 1990-2010 and Estimated 2020 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
HEALTH INSURANCE ISSUES AND TRENDS: UNITED STATES
Figure 2-12: Number of Insured vs. Uninsured in the United States 2005-2016
Figure 2-13: Number of Insured Children vs. Uninsured Children in the United States 2005-2016
Figure 2-14: Number of Insured Children vs. Uninsured Children in the United States 2005-2016
CONSUMER ISSUES AND TRENDS
Access to Professional Medical Services and the Link to Self-Medication
Figure 2-15: Practicing Physicians per 1,000 Population by Country, 2017 (Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Poland, Russia, Saudi Arabia, South Africa, Spain, Turkey, United Kingdom, United States, Venezuela)
REGULATORY SOLUTIONS TO OTC DRUG ACCESS
Revisions to Pharmaceutical Affairs Law (PAL) in Japan
Figure 2-16: Typical Pharmacist-Consumer OTC Drug Counseling Session
Changes to Australia’s OTC Drug Access – Up-scheduling Combination Medicines Containing
Codeine
Figure 2-17: National Classification System of Scheduling Medicines
CHAPTER THREE: OVER-THE-COUNTER CENTRAL NERVOUS SYSTEM AGENTS
MARKET SUMMARY
Figure 3-1: Global OTC Central Nervous System Agent Market, 2017-2023
MARKET BY DRUG SEGMENT
Figure 3-2: Global OTC Central Nervous System Agent Market, Distribution of Sales by Drug Segment 2017 (%)
MARKETS BY REGION
Asia Pacific
Figure 3-3: Asia Pacific OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
Europe
Figure 3-4: Europe OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
Latin America
Figure 3-5: Latin America OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
Middle East & Africa
Figure 3-6: Middle East & Africa OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
North America
Figure 3-7: North America OTC Central Nervous System Agent Market, 2017-2023 ($ millions)
CHAPTER FOUR: OVER-THE-COUNTER DERMATOLOGICAL AGENTS
MARKET SUMMARY
Figure 4-1: Global OTC Dermatological Agent Market, 2017-2023
MARKET BY DRUG SEGMENT
Figure 4-2: Global OTC Dermatological Agent Market, Distribution of Sales by Drug Segment 2017 (%) (Acne
Treatments, Antifungals/Antiinfectives, Hair Growth Remedies, Others)
MARKETS BY REGION
Asia Pacific
Figure 4-3: Asia Pacific OTC Dermatological Agent Market, 2017-2023 ($ millions)
Europe
Figure 4-4: Europe OTC Dermatological Agent Market, 2017-2023 ($ millions)
Latin America
Figure 4-5: Latin America OTC Dermatological Agent Market, 2017-2023 ($ millions)
Middle East & Africa
Figure 4-6: Middle East & Africa OTC Dermatological Agent Market, 2017-2023 ($ millions)
North America
Figure 4-7: North America OTC Dermatological Agent Market, 2017-2023 ($ millions)
CHAPTER FIVE: OVER-THE-COUNTER GASTROINTESTINAL SYSTEM AGENTS
MARKET SUMMARY
Figure 5-1: Global OTC Gastrointestinal Agent Market, 2017-2023
MARKET BY DRUG SEGMENT
Figure 5-2: Global Gastrointestinal OTC Market, Distribution of Sales by Drug Segment 2017 (%) (Laxatives, Antacids, Antidiarrheals, H2 Antagonists, Proton Pump Inhibitors)
MARKETS BY REGION
Asia Pacific
Figure 5-3: Asia Pacific OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
Europe
Figure 5-4: Europe OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
Latin America
Figure 5-5: Latin America OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
Middle East & Africa
Figure 5-6: Middle East & Africa OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
North America
Figure 5-7: North America OTC Gastrointestinal Agent Market, 2017-2023 ($ millions)
CHAPTER SIX: OVER-THE-COUNTER RESPIRATORY SYSTEM AGENTS
MARKET SUMMARY
Figure 6-1: Global OTC Respiratory Agent Market, 2017-2023
MARKET BY DRUG SEGMENT
Figure 6-2: Global OTC Respiratory Agent Market, Distribution of Sales by Drug Segment 2017 (%) (Antihistamines, Decongestants, Cough Preparations, Other Respiratory Agents)
Table 6-1: Global OTC Respiratory Agent Market, Sales by Indication, 2017-2023 ($ in millions) (Allergy/Asthma, Cough/Cold, Total)
Figure 6-3: Global OTC Respiratory Agent Market, Distribution of Sales by Indication 2017 (%) (Allergy/Asthma, Cough/Cold)
MARKETS BY REGION
Asia Pacific
Figure 6-4: Asia Pacific OTC Respiratory Agent Market, 2017-2023 ($ millions)
Europe
Figure 6-5: Europe OTC Respiratory Agent Market, 2017-2023 ($ millions)
Latin America
Figure 6-6: Latin America OTC Respiratory Agent Market, 2017-2023 ($ millions)
Middle East & Africa
Figure 6-7: Middle East & Africa OTC Respiratory Agent Market, 2017-2023 ($ millions)
North America
Figure 6-8: North America OTC Respiratory Agent Market, 2017-2023 ($ millions)
CHAPTER SEVEN: OVER-THE-COUNTER AGENTS VARIOUS THERAPEUTIC CLASSIFICATIONS
MARKET SUMMARY
Figure 7-1: Global OTC Other Therapies Market, 2017-2023
MARKETS BY REGION
Asia Pacific
Figure 7-2: Asia Pacific OTC Other Therapies Market, 2017-2023 ($ millions)
Europe
Figure 7-3: Europe OTC Other Therapies Market, 2017-2023 ($ millions)
Latin America
Figure 7-4: Latin America OTC Other Therapies Market, 2017-2023 ($ millions)
Middle East & Africa
Figure 7-5: Middle East & Africa OTC Other Therapies Market, 2017-2023 ($ millions)
North America
Figure 7-6: North America OTC Other Therapies Market, 2017-2023 ($ millions)
CHAPTER EIGHT: OTC DRUG MARKETS IN ASIA PACIFIC
REGIONAL OVERVIEW
Table 8-1: Asia Pacific Select Countries, Demographic Profile, 2017 and 2030 (Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Vietnam)
Figure 8-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Republic of Korea, Singapore, Taiwan, Thailand, Vietnam)
OTC DRUG SALES AND GROWTH IN ASIA PACIFIC MARKETS
Figure 8-2: OTC Drug Market in Asia Pacific Region, 2017-2023 (in millions of dollars at the manufacturers’ level)
Sales for OTC Drug Markets by Country
Figure 8-3: Asia Pacific OTC Drug Market Value by Country, 2017 and 2023 (Australia, China, India, Japan, Rest of Asia Pacific)
Figure 8-4: Asia Pacific OTC Drug Markets by Country, 2017 (%) (Australia, China, India, Japan, Rest of Asia Pacific)
Figure 8-5: OTC Drug Markets in Japan by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Figure 8-6: OTC Drug Markets in China by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Figure 8-7: OTC Drug Markets in India by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Figure 8-8: OTC Drug Markets in Australia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
ASIA PACIFIC OTC MARKETS BY THERAPEUTIC CLASS
Table 8-2: Asia-Pacific OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
Figure 8-9: Asia-Pacific OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
CHAPTER NINE: OTC DRUG MARKETS IN EUROPE
REGIONAL OVERVIEW
Table 9-1: Europe Select Countries, Demographic Profile, 2017 and 2030 (France, Germany, Italy, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom)
Figure 9-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (France, Germany, Italy, Poland, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom)
OTC DRUG SALES AND GROWTH IN EUROPE MARKETS
Figure 9-2: OTC Drug Market in Europe Region, 2017-2023 (in millions of dollars at the manufacturers’ level)
SALES FOR OTC DRUG MARKETS BY EUROPEAN COUNTRY
Figure 9-3: Europe OTC Drug Market Value by Country, 2017 and 2023 (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom)
Figure 9-4: Europe OTC Drug Markets by Country, 2017 (%) (France, Germany, Italy, Poland, Russia, Spain, Turkey, United Kingdom, Rest of Europe)
Germany
Figure 9-5: OTC Drug Markets in Germany by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
France
Figure 9-6: OTC Drug Markets in France by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Russia
Figure 9-7: OTC Drug Markets In Russia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
United Kingdom
Figure 9-8: OTC Drug Markets in The United Kingdom by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Italy
Figure 9-9: OTC Drug Markets in Italy by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Spain
Figure 9-10: OTC Drug Markets in Spain by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Poland
Figure 9-11: OTC Drug Markets in Poland by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Turkey
Figure 9-12: OTC Drug Markets in Turkey by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
EUROPE OTC MARKETS BY THERAPEUTIC CLASS
Table 9-2: Europe OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
Figure 9-13: Europe OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
CHAPTER TEN: OTC DRUG MARKETS IN LATIN AMERICA
REGIONAL OVERVIEW
Table 10-1: Latin America Select Countries, Demographic Profile, 2017 and 2030 (Argentina, Brazil, Chile, Mexico, Venezuela)
Figure 10-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Argentina, Brazil, Chile, Mexico, Venezuela)
OTC DRUG SALES AND GROWTH IN LATIN AMERICA MARKETS
Table 10-2: OTC Drug Market in Latin America Region, 2017-2023 (in millions of dollars at the manufacturers’ level)
SALES FOR OTC DRUG MARKETS BY COUNTRY
Figure 10-2: Latin America OTC Drug Market Value by Country, 2017 and 2023 (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)
Figure 10-3: Latin America OTC Drug Markets by Country, 2017 (%) (Argentina, Brazil, Mexico, Venezuela, Rest of Latin America)
Brazil
Figure 10-4: OTC Drug Markets in Brazil by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Mexico
Figure 10-5: OTC Drug Markets in Mexico by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Argentina
Figure 10-6: OTC Drug Markets in Argentina by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Venezuela
Figure 10-7: OTC Drug Markets in Venezuela by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
LATIN AMERICA OTC MARKETS BY THERAPEUTIC CLASS
Table 10-3: Latin America OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
Figure 10-8: Latin America OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
CHAPTER ELEVEN: OTC DRUG MARKETS IN MIDDLE EAST & AFRICA
REGIONAL OVERVIEW
Table 11-1: Middle East & Africa Select Countries, Demographic Profile, 2017 and 2030 (Egypt, Iran, Israel, Saudi Arabia, South Africa, UAE)
Figure 11-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Egypt, Iran, Israel, Saudi Arabia, South Africa, UAE)
OTC DRUG SALES AND GROWTH IN MIDDLE EAST & AFRICA MARKETS
Figure 11-2: OTC Drug Market in Middle East & Africa Region, 2017-2023 (in millions of dollars at the manufacturers’ level)
SALES FOR OTC DRUG MARKETS BY COUNTRY
Figure 11-3: Middle East & Africa OTC Drug Market Value by Country, 2017 and 2023 (Saudi Arabia, South Africa, Rest of Middle East & Africa)
Figure 11-4: OTC Drug Markets by Country, 2017 (%) (Saudi Arabia, South Africa, Rest of Middle East & Africa)
South Africa
Figure 11-5: OTC Drug Markets in South Africa by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Saudi Arabia
Figure 11-6: OTC Drug Markets in Saudi Arabia by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
MIDDLE EAST & AFRICA OTC MARKETS BY THERAPEUTIC CLASS
Table 11-2: Middle East & Africa OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
Figure 11-7: Middle East & Africa OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
CHAPTER TWELVE: OTC DRUG MARKETS IN NORTH AMERICA
REGIONAL OVERVIEW
Table 12-1: North America Select Countries, Demographic Profile, 2017 and 2030 (Canada, United States)
Figure 12-1: Population Growth vs. Aging Population Growth by Country, 2017-2030 (Canada, United States)
OTC DRUG SALES AND GROWTH IN NORTH AMERICA MARKETS
Figure 12-2: OTC Drug Markets in North America Region, 2017-2023 (in millions of dollars at the manufacturers’ level)
Sales for OTC Drug Markets by Country
Figure 12-3: North America OTC Drug Market Value by Country, 2017 and 2023 (Canada, United States, Rest of North America)
Figure 12-4: North America OTC Drug Markets by Country, 2017 (%) (Canada, United States, Rest of North America)
United States
Figure 12-5: OTC Drug Markets in the United States by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
Canada
Figure 12-6: OTC Drug Markets in Canada by Therapeutic Class, 2017 (%) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
NORTH AMERICA OTC MARKETS BY THERAPEUTIC CLASS
Table 12-2: North America OTC Drug Market Analysis by Therapeutic Class, 2017 and 2023 (in millions of dollars at the manufacturers’ level) (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other, Total)
Figure 12-7: North America OTC Drug Market by Therapeutic Class, 2017 and 2023 (Central Nervous System, Dermatological, Gastrointestinal, Respiratory, Other)
CHAPTER THIRTEEN: LEADING OTC DRUG MANUFACTURERS
OVERVIEW
COMPETITOR ANALYSIS
Table 13-1: Leading Suppliers Shares of the OTC Drug Market by Revenues—2017
Figure 13-1: Leading Suppliers Shares of the OTC Drug Market, 2017
A DECADE OF AGREEMENTS, MERGERS AND ACQUISITIONS SHAPING THE OTC DRUG MARKET
Sanofi and Boehringer Ingelheim
GlaxoSmithKline and Novartis AG
Bayer AG and Merck & Co.
Prestige Brands and Insight Pharmaceuticals
Perrigo Company Acquisitions
Procter & Gamble and Teva Pharmaceutical Industries
Sanofi and Chattem Consumer
Wyeth and Pfizer
Reckitt Benckiser and Adams Respiratory Therapeutics
LEADING CORPORATE PROFILES
Bayer AG
Table 13-2: Bayer Corporate Summary
Table 13-3: Bayer Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December) .. 153
GlaxoSmithKline plc
Table 13-4: GlaxoSmithKline Corporate Summary
Table 13-5: GlaxoSmithKline Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Johnson & Johnson
Table 13-6: Johnson & Johnson Corporate Summary
Table 13-7: Johnson & Johnson Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Mylan N.V.
Table 13-8: Mylan Corporate Summary
Table 13-9: Mylan Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Perrigo Company plc
Table 13-10: Perrigo Company Corporate Summary
Table 13-11: Perrigo Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Pfizer, Inc.
Table 13-12: Pfizer Corporate Summary
Table 13-13: Pfizer Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Procter & Gamble Company
Table 13-14: Procter & Gamble Company Corporate Summary
Table 13-15: Procter & Gamble Recent Revenue History, 2015-2017 (US$ Millions, financial year ending June)
Reckitt Benckiser Group Plc
Table 13-16: Reckitt Benckiser Group Corporate Summary
Table 13-17: Reckitt Benckiser Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Sanofi
Table 13-18: Sanofi Corporate Summary
Table 13-19: Sanofi Recent Revenue History, 2015-2017 (US$ Millions, financial year ending December)
Taisho Pharmaceutical Holding Co., Ltd.
Table 13-20: Taisho Pharmaceutical Holding Corporate Summary
Table 13-21: Taisho Pharmaceutical Recent Revenue History, FY End 2016-2017 (US$ Millions, financial year ending March)
